British Inflammation Research Association meeting: is there any point in developing an anti-RA drug? National Heart and Lung Institute, London, UK, 21-22 November 1996.
Clay
F
F
R & D Systems Europe, Abingdon, UK. frances@rndsystems.co.uk
Morris
C
C
D000700:Analgesics / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics / Q000503:physiopathology; D002097:C-Reactive Protein / Q000378:metabolism*; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000378:metabolism; D015195:Drug Design; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D016207:Cytokines; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D002097:C-Reactive Protein